

# Miguel Martin

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2029886/miguel-martin-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

374  
papers

20,173  
citations

69  
h-index

136  
g-index

447  
ext. papers

24,875  
ext. citations

6.2  
avg, IF

6.24  
L-index

#	Paper	IF	Citations
374	Genetic polymorphisms and correlation with treatment induced cardiotoxicity and prognosis in breast cancer patients.. <i>Clinical Cancer Research</i> , <b>2022</b> ,	12.9	1
373	Prognosis and correlation with Ca19.9 of circulating tumor cells (CTCs) in locally advanced and metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 586-586	2.2	
372	Abstract GS1-07: Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial. <i>Cancer Research</i> , <b>2022</b> , 82, GS1-07-GS1-07	10.1	
371	Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) + anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. <b>2022</b> , 10,		3
370	Abstract PD13-01: Balixafortide (a CXCR4 antagonist)+eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer: An international, randomized, phase 3 trial (FORTRESS). <i>Cancer Research</i> , <b>2022</b> , 82, PD13-01-PD13-01	10.1	
369	Code of practice needed for samples donated by trial participants.. <i>Lancet Oncology, The</i> , <b>2022</b> , 23, e89-e90	20.7	2
368	Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.. <i>European Journal of Cancer</i> , <b>2022</b> , 168, 12-24	7.5	1
367	The importance of physical exercise in cardiovascular fitness in breast cancer survivors. A cross-sectional study: women in Motion 2.0.. <i>Supportive Care in Cancer</i> , <b>2022</b> , 1	3.9	0
366	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.. <i>Lancet Oncology, The</i> , <b>2021</b> ,	21.7	16
365	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). <i>Journal of Clinical Oncology</i> , <b>2021</b> , JCO2102554	2.2	11
364	21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 2336-2347	59.2	45
363	Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. <i>Annals of Oncology</i> , <b>2021</b> , 32, 1571-1581	10.3	36
362	nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , <b>2021</b> , 21, 181-190.e2	3	7
361	Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study. <i>Journal of Gastrointestinal Cancer</i> , <b>2021</b> , 52, 814-818	1.6	2
360	Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts. <i>Scientific Reports</i> , <b>2021</b> , 11, 7064	4.9	3
359	Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL. <i>Annals of Oncology</i> , <b>2021</b> , 32, 488-499	10.3	16
358	How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer. <i>Oncology and Therapy</i> , <b>2021</b> , 9, 297-309	2.7	1

357	acelERA Breast Cancer (BC): Phase II study evaluating efficacy and safety of giredestrant (GDC-9545) versus physician's choice of endocrine monotherapy in patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) locally advanced or metastatic breast cancer (LA/mBC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS1100-TPS1100	2.2	1
356	Reply to K. Hashimoto and A. Shimomura. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1507-1508	2.2	
355	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1518-1530	2.2	35
354	Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 517-517	2.2	2
353	Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups. <i>Npj Breast Cancer</i> , <b>2021</b> , 7, 80	7.8	2
352	Prognostic value of molecular biomarkers in patients with metastatic colorectal cancer: a real-world study. <i>Clinical and Translational Oncology</i> , <b>2021</b> , 23, 122-129	3.6	0
351	Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine-Induced Hand-Foot Syndrome. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 109, 462-470	6.1	0
350	Aggressiveness of end-of-life cancer care: what happens in clinical practice?. <i>Supportive Care in Cancer</i> , <b>2021</b> , 29, 3121-3127	3.9	0
349	Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. <i>Clinical Breast Cancer</i> , <b>2021</b> , 21, 80-91.e7	3	52
348	At the Bedside: Profiling and treating patients with CXCR4-expressing cancers. <i>Journal of Leukocyte Biology</i> , <b>2021</b> , 109, 953-967	6.5	4
347	Iterative Variable Selection for High-Dimensional Data: Prediction of Pathological Response in Triple-Negative Breast Cancer. <i>Mathematics</i> , <b>2021</b> , 9, 222	2.3	2
346	Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice. <i>Supportive Care in Cancer</i> , <b>2021</b> , 29, 4673-4681	3.9	
345	Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. <i>Npj Breast Cancer</i> , <b>2021</b> , 7, 1	7.8	54
344	Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. <i>JCO Global Oncology</i> , <b>2021</b> , 7, 162-172	3.7	16
343	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 212-222	21.7	64
342	Alpelisib in combination with everolimus+ exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. <i>European Journal of Cancer</i> , <b>2021</b> , 151, 49-62	7.5	5
341	Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. <i>Annals of Oncology</i> , <b>2021</b> , 32, 1015-1024	10.3	27
340	Venous thromboembolism incidence in cancer patients with germline BRCA mutations. <i>Clinical and Translational Oncology</i> , <b>2021</b> , 1	3.6	0

339	Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population. <i>Breast Cancer Research and Treatment</i> , <b>2021</b> , 189, 689-699	4.4	7
338	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
337	Trajectories of alcohol consumption during life and the risk of developing breast cancer. <i>British Journal of Cancer</i> , <b>2021</b> , 125, 1168-1176	8.7	0
336	Reply to Y. Usui et al. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2113-2114	2.2	
335	Nephrotic syndrome in a 60-year-old man. <i>Journal of Clinical Pathology</i> , <b>2020</b> , 73, e3	3.9	
334	Neratinib for the treatment of early-stage, hormone receptor-positive, HER2-overexpressed breast cancer. <i>Future Oncology</i> , <b>2020</b> , 16, 1165-1177	3.6	1
333	Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer. <i>Oncologist</i> , <b>2020</b> , 25, e1346-e1354	5.7	13
332	Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLEET population. <i>Clinical and Translational Oncology</i> , <b>2020</b> , 22, 1857-1866	3.6	1
331	Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy. <i>JNCI Cancer Spectrum</i> , <b>2020</b> , 4, pkz085	4.6	15
330	Etiology and Prognosis of Pneumonia in Patients with Solid Tumors: A Prospective Cohort of Hospitalized Cases. <i>Oncologist</i> , <b>2020</b> , 25, e861-e869	5.7	2
329	Exercise and cancer: a position statement from the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , <b>2020</b> , 22, 1710-1729	3.6	18
328	Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifestuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 364-372	12.9	12
327	Abstract CT071: Talazoparib (TALA) in germlineBRCA1/2(gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): Final overall survival (OS) results from randomized Phase 3 EMBRACA trial <b>2020</b> ,		4
326	Abstract GS1-07: Effects of capecitabine as part of neo-/adjuvant chemotherapy. A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients <b>2020</b> ,		10
325	Abstract GS2-07: Results from PEARL study (GEICAM/2013-02_CECO/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors		10
324	Abstract GS5-01: Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis <b>2020</b> ,		13
323	Abstract P3-09-19: Preliminary safety data of intrahepatic talimogene laherparepvec and intravenous atezolizumab in patients with triple negative breast cancer <b>2020</b> ,		3
322	Situation, challenges, and SEOM recommendations for the future of undergraduate education in Oncology in Spain. <i>Clinical and Translational Oncology</i> , <b>2020</b> , 22, 1049-1058	3.6	

321	Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR/HER2 Breast Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 566-580	12.9	65
320	Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 110-121	12.9	57
319	Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 203-213	2.2	45
318	Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations. <i>Drugs</i> , <b>2020</b> , 80, 131-146	12.1	8
317	Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 514-524	59.2	251
316	Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , <b>2020</b> , 21, 60-72	21.7	85
315	Outcomes of COVID-19 in Patients With Lung Cancer Treated in a Tertiary Hospital in Madrid. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1777	5.3	14
314	Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study. <i>Breast</i> , <b>2020</b> , 54, 148-154	3.6	8
313	GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain. <i>Oncologist</i> , <b>2020</b> , 25, e1339-e1345	5.7	7
312	Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study. <i>Scientific Reports</i> , <b>2020</b> , 10, 7741	4.9	4
311	Association Between ABCB1 Genetic Variants and Persistent Chemotherapy-Induced Alopecia in Women With Breast Cancer. <i>JAMA Dermatology</i> , <b>2020</b> , 156, 987-991	5.1	3
310	Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer. <i>Future Oncology</i> , <b>2020</b> , 16, 2763-2778	3.6	2
309	Serum Phospholipids Fatty Acids and Breast Cancer Risk by Pathological Subtype. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	2
308	Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3987-3998	22.2	152
307	Oncological care organisation during COVID-19 outbreak. <i>ESMO Open</i> , <b>2020</b> , 5,	6	18
306	Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience. <i>Clinical and Translational Oncology</i> , <b>2020</b> , 22, 717-724	3.6	4
305	Efficacy and safety of immune checkpoint inhibitor immunotherapy in elderly cancer patients. <i>Clinical and Translational Oncology</i> , <b>2020</b> , 22, 555-562	3.6	5
304	Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2. <i>Clinical Breast Cancer</i> , <b>2020</b> , 20, e179-e189	3	10

303	Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 175, 129-139	4.4	5
302	MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. <i>Npj Breast Cancer</i> , <b>2019</b> , 5, 5	7.8	176
301	Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial. <i>Annals of Oncology</i> , <b>2019</b> , 30, 567-574	10.3	11
300	Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine + pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. <i>BMC Cancer</i> , <b>2019</b> , 19, 517	4.8	18
299	Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2206-2216	2.2	78
298	Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series. <i>BMC Genomics</i> , <b>2019</b> , 20, 452	4.5	12
297	Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 177, 115-125	4.4	7
296	IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. <i>Future Oncology</i> , <b>2019</b> , 15, 1951-1961	3.6	33
295	A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 303	5.3	3
294	Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 176, 377-386	4.4	39
293	PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial. <i>Breast Cancer Research</i> , <b>2019</b> , 21, 39	8.3	11
292	Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study. <i>Scientific Reports</i> , <b>2019</b> , 9, 3904	4.9	12
291	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , <b>2019</b> , 393, 1440-1452	4.0	137
290	A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothed or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study. <i>Investigational New Drugs</i> , <b>2019</b> , 37, 98-108	4.3	22
289	Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE. <i>Cancer</i> , <b>2019</b> , 125, 3974-3984	6.4	31
288	Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. <i>European Journal of Cancer</i> , <b>2019</b> , 117, 91-98	7.5	9
287	B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer. <i>Cell</i> , <b>2019</b> , 179, 1191-1206.e21	56.2	146
286	Interim results from the full population of the phase 3b ComPLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2-advanced breast cancer (ABC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1041-1041	2.2	1

285	Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1071-1071	2.2	1
284	Balixafortide (a CXCR4 antagonist) + eribulin in HER2-negative metastatic breast cancer (MBC): Survival outcomes of the phase I trial.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2606-2606	2.2	2
283	Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 500-500	2.2	4
282	Incidence of venous thromboembolic disease (VTE) in a cohort of patients with colorectal cancer (CRC) according to KRAS, NRAS and BRAF status.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e15136-e15136	2.2	1
281	NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS597-TPS597	2.2	23
280	Retrospective analysis of clinical characteristics of mCRC patients receiving three or more lines of chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 682-682	2.2	
279	Phase Ib study of talimogene laherparepvec (T-VEC) injection into liver metastases (LMs) in combination with intravenous (IV) atezolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS725-TPS725	2.2	
278	Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval. <i>Oncotarget</i> , <b>2019</b> , 10, 4321-4332	3.3	
277	Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement. <i>Oncologist</i> , <b>2019</b> , 24, 603-611	5.7	20
276	Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry). <i>Scientific Reports</i> , <b>2019</b> , 9, 20081	4.9	6
275	Concordance of Genomic Variants in Matched Primary Breast Cancer, Metastatic Tumor, and Circulating Tumor DNA: The MIRROR Study.. <i>JCO Precision Oncology</i> , <b>2019</b> , 3, 1-16	3.6	3
274	Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines. <i>JAMA Oncology</i> , <b>2019</b> , 5, 366-375	13.4	17
273	Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 812-824	21.7	70
272	Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1195-1202	10.3	8
271	Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 1845-1852	12.9	47
270	First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study. <i>Breast</i> , <b>2018</b> , 38, 144-149	3.6	8
269	Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. <i>Annals of Oncology</i> , <b>2018</b> , 29, 888-894	10.3	72
268	Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit. <i>Journal of Genetic Counseling</i> , <b>2018</b> , 27, 854-862	2.5	3

267	Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. <i>Annals of Oncology</i> , <b>2018</b> , 29, 669-680	10.3	49
266	Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 1056-1061	8.7	61
265	Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study. <i>European Journal of Cancer</i> , <b>2018</b> , 94, 199-205	7.5	14
264	Proposal for the creation of a national strategy for precision medicine in cancer: a position statement of SEOM, SEAP, and SEFH. <i>Clinical and Translational Oncology</i> , <b>2018</b> , 20, 443-447	3.6	20
263	Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 167, 249-256	4.4	15
262	Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 5820-5829	12.9	47
261	Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. <i>Nature Communications</i> , <b>2018</b> , 9, 2897	17.4	182
260	Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1939-1947	10.3	65
259	Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 753-763	59.2	862
258	The LILAC trial and the blooming of anticancer biosimilars. <i>Lancet Oncology</i> , <b>2018</b> , 19, 861-863	21.7	1
257	Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 171, 627-634	4.4	16
256	Abstract PD3-06: Association of intrinsic subtypes with pathological complete response (pCR) in the KRISTINE neoadjuvant phase 3 clinical trial in HER2-positive early breast cancer (EBC) <b>2018</b> ,		10
255	Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from MONALEESA-3.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1000-1000	2.2	12
254	The association of early toxicity and outcomes for patients treated with abemaciclib.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1053-1053	2.2	6
253	Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompleEment-1 trial.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1056-1056	2.2	2
252	EMBRACA: Efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1069-1069	2.2	4
251	Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3014-3014	2.2	22
250	Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 501-501	2.2	48

249	Timing of initiation of neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ hormone receptor (HR)-negative breast cancer: Exploratory analyses from the phase III ExteNET trial.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 549-549	2.2	3
248	IMpassion132: A double-blind randomized phase 3 trial evaluating chemotherapy (CT) + atezolizumab (atezo) for early progressing locally advanced/metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS1115-TPS1115	2.2	1
247	Prognostic and predictive factors in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 690-690	2.2	1
246	Dietary inflammatory index and breast cancer risk by menopausal status and histological subtype.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1521-1521	2.2	
245	Chemotherapy Plus Bevacizumab as Neoadjuvant or Conversion Treatment in Patients with Colorectal Liver Metastases. <i>Anticancer Research</i> , <b>2018</b> , 38, 3069-3077	2.3	1
244	Abstract CT099: The benefit of abemaciclib in prognostic subgroups: An update to the pooled analysis of MONARCH 2 and 3 <b>2018</b> ,		2
243	Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from MONALEESA-3 <b>2018</b> , 78,		2
242	Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 115-126	21.7	203
241	Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2465-2472	2.2	435
240	Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1073-1079	2.2	62
239	Subcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysis. <i>Annals of Oncology</i> , <b>2018</b> , 29, viii103	10.3	2
238	Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. <i>Npj Breast Cancer</i> , <b>2018</b> , 4, 41	7.8	30
237	Intratumoral BO-112, a double-stranded RNA (dsRNA), alone and in combination with systemic anti-PD-1 in solid tumors. <i>Annals of Oncology</i> , <b>2018</b> , 29, viii732	10.3	5
236	Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase gene. <i>Cancer Management and Research</i> , <b>2018</b> , 10, 4517-4522	3.6	2
235	Pharmacogenetic variants and response to neoadjuvant single-agent doxorubicin or docetaxel: a study in locally advanced breast cancer patients participating in the NCT00123929 phase 2 randomized trial. <i>Pharmacogenetics and Genomics</i> , <b>2018</b> , 28, 245-250	1.9	0
234	Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4072-4080	12.9	15
233	Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy. <i>Clinical and Translational Oncology</i> , <b>2018</b> , 20, 1548-1556	3.6	9
232	Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 649-657	12.9	75

231	Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 141-148	2.2	246
230	Strategies to design clinical studies to identify predictive biomarkers in cancer research. <i>Cancer Treatment Reviews</i> , <b>2017</b> , 53, 79-97	14.4	64
229	The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?. <i>Breast</i> , <b>2017</b> , 33, 191-199	3.6	3
228	A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 3035-3044	12.9	17
227	Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 162, 181-189	4.4	10
226	Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists. <i>Clinical and Translational Oncology</i> , <b>2017</b> , 19, 508-518	3.6	10
225	Physical activity and breast cancer risk by pathological subtype. <i>Gynecologic Oncology</i> , <b>2017</b> , 144, 577-584	4.9	27
224	Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM "El Eamo III" retrospective study. <i>PLoS ONE</i> , <b>2017</b> , 12, e0184181	3.7	
223	A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study. <i>Oncotarget</i> , <b>2017</b> , 8, 73144-73153	3.3	19
222	Tuning up adjuvant endocrine therapy: the TEAM trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 1145-1146	21.7	1
221	Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer. <i>Future Oncology</i> , <b>2017</b> , 13, 2137-2149	3.6	6
220	Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis. <i>Oncologist</i> , <b>2017</b> , 22, 1301-1308	5.7	10
219	Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer. <i>Breast Care</i> , <b>2017</b> , 12, 296-302	2.4	6
218	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 1688-1700	21.7	328
217	Neratinib for the treatment of HER2-positive early stage breast cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2017</b> , 17, 669-679	3.5	16
216	RE: Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109, 1	9.7	2
215	A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4). <i>Annals of Oncology</i> , <b>2017</b> , 28, 313-320	10.3	102
214	Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions. <i>Clinical and Translational Oncology</i> , <b>2017</b> , 19, 341-356	3.6	5

213	Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial. <i>Annals of Surgical Oncology</i> , <b>2017</b> , 24, 398-406	3.1	18
212	Phase III, randomized study of first-line trastuzumab emtansine (T-DM1) + pertuzumab (P) vs. trastuzumab + taxane (HT) treatment of HER2-positive MBC: Final overall survival (OS) and safety from MARIANNE.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1003-1003	2.2	6
211	Phase I study of the combination of balixafortide (CXCR4 inhibitor) and eribulin in HER2-negative metastatic breast cancer (MBC) patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2555-2555	2.2	2
210	First-in-human clinical trial with intratumoral BO-112 in solid malignancies: A novel immunotherapy based in double-stranded RNA (dsRNA).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3082-3082	2.2	2
209	Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 21930-21937	3.3	10
208	Evaluating the addition of bevacizumab (Bev) to endocrine therapy as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1010-1010	2.2	
207	A phase 2 study of investigational TORC1/2 inhibitor TAK-228 with fulvestrant in women with ER+/HER2-advanced or metastatic breast cancer (mBC) that has progressed during or after aromatase inhibitor (AI) therapy.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS1118-TPS1118	2.2	
206	Proposal for the Creation of a National Strategy for Precision Medicine in Cancer: a position statement of SEOM, SEAP and SEFH. <i>Farmacia Hospitalaria</i> , <b>2017</b> , 41, 688-691	0.9	2
205	Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 97, 96-106	7	31
204	HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3518-3528	2.2	92
203	Endocrine therapy for hormone treatment-naïve advanced breast cancer. <i>Breast</i> , <b>2016</b> , 28, 161-6	3.6	6
202	Palbociclib and Letrozole in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1925-1936	10.36	1278
201	Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. <i>European Journal of Cancer</i> , <b>2016</b> , 56, 85-92	7.5	4
200	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , <b>2016</b> , 17, 367-377	21.7	339
199	Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. <i>Supportive Care in Cancer</i> , <b>2016</b> , 24, 447-455	3.9	114
198	Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 156, 81-9	4.4	35
197	Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. <i>Annals of Oncology</i> , <b>2016</b> , 27, 379-90	10.3	135
196	Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. <i>European Journal of Cancer</i> , <b>2016</b> , 53, 75-83	7.5	77

195	S-1 versus taxanes for HER2-negative metastatic breast cancer. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 11-2	21.7	2
194	Abstract CT061: A phase Ib study of alpelisib (BYL719) + everolimus + exemestane in patients with advanced solid tumors or HR+/HER2-breast cancer <b>2016</b> ,		7
193	Abstract CT092: A phase II study of neoadjuvant abemaciclib (LY2835219) in postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer (neoMONARCH) <b>2016</b> ,		3
192	Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 500-500	2.2	28
191	PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2-advanced breast cancer (ABC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 507-507	2.2	58
190	Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC) who have received no or only one line of prior endocrine therapy (EP) (MOMENTUM3).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TP6121-TP6121	2.2	10
189	Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile. <i>Current Cancer Drug Targets</i> , <b>2016</b> , 16, 415-28	2.8	8
188	A Cross-Sectional Comparison of Druggable Mutations in Primary Tumors, Metastatic Tissue, Circulating Tumor Cells, and Cell-Free Circulating DNA in Patients with Metastatic Breast Cancer: The MIRROR Study Protocol. <i>JMIR Research Protocols</i> , <b>2016</b> , 5, e167	2	6
187	Outcomes of single versus double hormone receptor positive breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 569-569	2.2	
186	Implication of MODEL of financing clinical research in breast cancer during the past two decades.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e14046-e14046	2.2	
185	Patient-reported outcomes (PROs) from MARIANNE: A phase III study of trastuzumab emtansine (T-DM1) +/- pertuzumab (P) vs trastuzumab + taxane (HT) for HER2-positive advanced breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 593-593	2.2	
184	HER2 gene amplification testing by fluorescence in situ hybridization (FISH): Comparison of the ASCO-CAP guidelines with FISH scores used for enrollment in breast cancer international research group (BCIRG) clinical trials.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 515-515	2.2	1
183	The implementation of a multidisciplinary hereditary cancer unit to increase the referral and preventive surgeries of breast cancer patients with genetic risk in a university hospital.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e13031-e13031	2.2	
182	Exclusion criteria vs reality: dual BRAF/MEK inhibition and radiotherapy in a patient with melanoma metastatic to the brain and ECOG 3. <i>Tumori</i> , <b>2016</b> , 102,	1.7	3
181	Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLETT).. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1719-25	10.3	55
180	SEOM Clinical Guideline for bone metastases from solid tumours (2016). <i>Clinical and Translational Oncology</i> , <b>2016</b> , 18, 1243-1253	3.6	20
179	Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene. <i>Clinical Breast Cancer</i> , <b>2016</b> , 16, 364-371	3	4
178	Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 156, 507-515	4.4	22

177	Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1249-56	10.3	22
176	Final Survival Analysis of ROSE/TRIO-012. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3714-3715	2.2	
175	Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1045-52	2.2	97
174	Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 685-96	7.5	7
173	Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1574-83	2.2	112
172	Defining breast cancer intrinsic subtypes by quantitative receptor expression. <i>Oncologist</i> , <b>2015</b> , 20, 474-82	8.7	102
171	Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3788-95	2.2	43
170	Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer. <i>Current Medical Research and Opinion</i> , <b>2015</b> , 31, 1129-37	2.5	25
169	Supervised physical exercise improves VO2max, quality of life, and health in early stage breast cancer patients: a randomized controlled trial. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 153, 371-82	4.4	54
168	Levels and predictors of persistent organic pollutants in an adult population from four Spanish regions. <i>Science of the Total Environment</i> , <b>2015</b> , 538, 152-61	10.2	25
167	Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis. <i>Oncologist</i> , <b>2015</b> , 20, 111-2	5.7	15
166	A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. <i>Gut</i> , <b>2015</b> , 64, 111-20	19.2	74
165	Running away from side effects: physical exercise as a complementary intervention for breast cancer patients. <i>Clinical and Translational Oncology</i> , <b>2015</b> , 17, 180-96	3.6	27
164	nab-Paclitaxel dose and schedule in breast cancer. <i>Breast Cancer Research</i> , <b>2015</b> , 17, 81	8.3	16
163	Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. <i>Breast Cancer Research</i> , <b>2015</b> , 17, 56	8.3	21
162	El cáncer de mama. <i>Arbor</i> , <b>2015</b> , 191, a234	0.2	3
161	Lower Breast Cancer Risk among Women Following Lifestyle Recommendations: A Case-Control Study in Spain.. <i>International Journal of Epidemiology</i> , <b>2015</b> , 44, i136-i136	7.8	
160	PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 2065-74	12.9	47

159	Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 141-8	2.2	90
158	Abstract P5-19-02: Everolimus in combination with exemestane in hormone receptor-positive locally advanced or metastatic breast cancer (BC) patients progressing on prior non-steroidal AI (NSAIs): Ballet study (CRAD001YIC04) <b>2015</b> ,		2
157	Abstract P6-08-10: Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in women with estrogen receptor-positive, HER2-negative, node-negative breast cancer: A GEICAM study <b>2015</b> ,		2
156	Phase III, randomized study of trastuzumab emtansine (T-DM1) + pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 507-507	2.2	41
155	Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 508-508	2.2	12
154	A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS1107-TPS1107	2.2	9
153	Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 117-117	2.2	1
152	Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study. <i>PLoS ONE</i> , <b>2015</b> , 10, e0126096	3.7	39
151	Bevacizumab plus Letrozol (LEA clinical trial phase III). Using hypertension for finding biomarkers of efficacy.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2524-2524	2.2	
150	Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 547-547	2.2	1
149	Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. <i>Lancet Oncology</i> , <b>2014</b> , 15, 156-63	21.7	148
148	Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3626-33 <sup>2</sup>	2.2	96
147	Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1031-9 <sup>2</sup>	2.2	164
146	Predicting response and survival in chemotherapy-treated triple-negative breast cancer. <i>British Journal of Cancer</i> , <b>2014</b> , 111, 1532-41	8.7	82
145	Cyclin Kinase Inhibitors in Breast Cancer: From Bench to Bedside. <i>Current Breast Cancer Reports</i> , <b>2014</b> , 6, 79-87	0.8	3
144	Phase III Study of Palbociclib in Combination with Exemestane Vs. Capecitabine, in Hormonal Receptor (Hr) Positive/Her2 Negative Metastatic Breast Cancer (Mbc) Patients with Resistance to Non-Steroidal Aromatase Inhibitors (Nsai): Pearl Study (Geicam/2013-02_Cecog/Bc.1.3.006). <i>Annals of Oncology</i> , <b>2014</b> , 25, iv134	10.3	2
143	Spanish Mediterranean diet and other dietary patterns and breast cancer risk: case-control EpiGEICAM study. <i>British Journal of Cancer</i> , <b>2014</b> , 111, 1454-62	8.7	104
142	Adoption of Multi-Gene Assays in HR +, HER2 Breast Cancer (BC) Patients in Europe: Results of the Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) Survey. <i>Annals of Oncology</i> , <b>2014</b> , 25, i5	10.3	2

141	Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses. <i>Pharmacogenetics and Genomics</i> , <b>2014</b> , 24, 231-7	1.9	9
140	Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106, djt337	9.7	181
139	Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2-breast cancer patients: results from the GEICAM 9906 trial. <i>Breast Cancer Research</i> , <b>2014</b> , 16, R38	8.3	97
138	Evaluation of a hereditary cancer unit in increasing family history collection and genetic counseling referrals among Spanish oncologists at a university hospital. <i>Journal of Genetic Counseling</i> , <b>2014</b> , 23, 108-13	2.5	3
137	Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient's management and therapy selection. <i>Clinical and Translational Oncology</i> , <b>2014</b> , 16, 386-94	3.6	14
136	Vinflunine plus capecitabine for advanced breast cancer previously treated with or resistant to anthracycline and resistant to taxane: A phase III study versus capecitabine.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1013-1013	2.2	1
135	Nabrax: Neoadjuvant therapy of breast cancer with weekly single-agent nab-paclitaxel: Final efficacy and biomarkers analysis of GEICAM 2011-02 trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1051-1051	2.2	2
134	A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 587-587	2.2	18
133	Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal-related events (SREs) in patients with metastatic bone disease: Subgroup analyses by baseline characteristics.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 9501-9501	2.2	2
132	Metastatic melanoma with spontaneous regression, psoriasis and HLA-Cw6: case report and a hypothesis to explore. <i>Tumori</i> , <b>2014</b> , 100, 144e-7e	1.7	2
131	Subtype analysis from the GEICAM/2003-02 study: High-risk, node-negative breast cancer patients treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 11107-11107	2.2	
130	Breast cancer risk among women following lifestyle recommendations: A case-control study in Spain.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1602-1602	2.2	
129	Denosumab for the treatment of bone metastases in advanced breast cancer. <i>Breast</i> , <b>2013</b> , 22, 585-92	3.6	18
128	Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2013</b> , 13, 381-91	2.2	14
127	Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study. <i>Oncologist</i> , <b>2013</b> , 18, 812-8	5.7	14
126	Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. <i>Lancet Oncology</i> , <b>2013</b> , 14, 72-80	21.7	164
125	Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 203-9	2.2	376
124	A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 3763-72	7.5	112

123	Zooming in on the schedule of bone-modifying drugs. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 575-6	21.7	4
122	Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 88-96	21.7	112
121	Chemotherapy: Maintenance therapy in breast cancer--many questions remain. <i>Nature Reviews Clinical Oncology</i> , <b>2013</b> , 10, 370-2	19.4	4
120	The evolving landscape of protein kinases in breast cancer: clinical implications. <i>Cancer Treatment Reviews</i> , <b>2013</b> , 39, 68-76	14.4	19
119	Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology. <i>Breast Cancer Research and Treatment</i> , <b>2013</b> , 138, 149-55	4.4	10
118	PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2013</b> , 138, 457-66	4.4	78
117	Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials. <i>Onkologie</i> , <b>2013</b> , 36, 363-7		3
116	Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2593-9	2.2	45
115	Circulating tumor cells following first chemotherapy cycle: an early and strong predictor of outcome in patients with metastatic breast cancer. <i>Oncologist</i> , <b>2013</b> , 18, 917-23	5.7	33
114	Reply to Y.Yamamoto et al. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2517-8	2.2	2
113	A randomized phase II non-comparative study of pemetrexed-carboplatin and gemcitabine-vinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients. <i>International Journal of Oncology</i> , <b>2013</b> , 42, 1778-85	4.4	10
112	Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. <i>Breast Cancer Research</i> , <b>2013</b> , 15, R105	8.3	50
111	A randomized, multicenter, double-blind phase III study of palbociclib (PD-0332991), an oral CDK 4/6 inhibitor, plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anticancer treatment for advanced disease.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS652-TPS652	2.2	6
110	Pharmacogenetic biomarkers for predisposition to toxicity to adjuvant FOLFOX/XELOX in colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 390-390	2.2	
109	Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, placebo-controlled, randomized, double-blind phase III clinical trial.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS662-TPS662	2.2	
108	Final results of a phase II trial of trabectedin (T) in patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to xeroderma pigmentosum gene (XPG) expression.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 547-547	2.2	0
107	Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. <i>Breast</i> , <b>2012</b> , 21, 20-6	3.6	24
106	Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial. <i>Cancer</i> , <b>2012</b> , 118, 241-7	6.4	25

105	Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. <i>Supportive Care in Cancer</i> , <b>2012</b> , 20, 2661-8	3.9	29
104	Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 134, 903-13	4.4	38
103	Neoadjuvant treatments for triple-negative breast cancer (TNBC). <i>Annals of Oncology</i> , <b>2012</b> , 23 Suppl 6, vi35-9	10.3	94
102	Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 482-91	7.5	10
101	PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. <i>BMC Medical Genomics</i> , <b>2012</b> , 5, 44	3.7	199
100	Family history record and hereditary cancer risk perception according to National Cancer Institute criteria in a Spanish medical oncology service: a retrospective study. <i>Oncology</i> , <b>2012</b> , 82, 30-4	3.6	6
99	Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes. <i>PLoS ONE</i> , <b>2012</b> , 7, e42494	3.7	7
98	Neratinib (HKI-272) in the treatment of breast cancer. <i>Future Oncology</i> , <b>2012</b> , 8, 671-81	3.6	23
97	Incidence-based cost-of-illness model for metastatic breast cancer in the United States. <i>International Journal of Technology Assessment in Health Care</i> , <b>2012</b> , 28, 12-21	1.8	46
96	Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?. <i>Clinical and Translational Oncology</i> , <b>2012</b> , 14, 163-8	3.6	19
95	Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. <i>Annals of Oncology</i> , <b>2012</b> , 23, 625-631	10.3	93
94	Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 4841-9	12.9	102
93	Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer. <i>Oncologist</i> , <b>2012</b> , 17, 469-75	5.7	39
92	Differences in the therapeutic approach to colorectal cancer in young and elderly patients. <i>Oncologist</i> , <b>2012</b> , 17, 1277-85	5.7	43
91	Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. <i>Circulation</i> , <b>2012</b> , 126, 2749-63	16.7	148
90	Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 3478-86	12.9	89
89	Randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer (BC) comparing FAC with FAC followed by weekly paclitaxel: First efficacy analysis of the GEICAM/2003-02 trial.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1001-1001	2.2	1
88	Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: A collaborative effort of the BIG-NCI NABCG.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1008-1008	2.2	12

87	A phase II trial of trabectedin (T) in patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to xeroderma pigmentosum gene (XPG) expression.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, TPS652-TPS652	2.2	1
86	Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, LBA671-LBA671	2.2	34
85	Family history record and hereditary cancer risk perception after the creation of a hereditary cancer unit in a Spanish hospital.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e12003-e12003	2.2	
84	Prognostic value of KRAS in terms of efficacy and safety of bevacizumab as neoadjuvant or conversion treatment in patients with colorectal liver metastasis.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e14058-e14058	2.2	
83	Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE): An international, randomized, double-blind, placebo-controlled phase III clinical trial.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, TPS670-TPS670	2.2	
82	Adjuvant trastuzumab in HER2-positive breast cancer. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 1273-82	3.2	1788
81	Assessment of Topoisomerase II $\beta$ status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization. <i>American Journal of Pathology</i> , <b>2011</b> , 178, 1453-60	5.8	55
80	Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. <i>Lancet Oncology</i> , <b>2011</b> , 12, 369-76	21.7	68
79	Characterization of uncertainty in the classification of multivariate assays: application to PAM50 centroid-based genomic predictors for breast cancer treatment plans. <i>Journal of Clinical Bioinformatics</i> , <b>2011</b> , 1, 37		15
78	Regional and seasonal influence in patient's toxicity to adjuvant chemotherapy for early breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 125, 273-8	4.4	4
77	Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 128, 127-36	4.4	61
76	Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelial ovarian cancer patients. Long-term single institution experience and literature review. <i>Clinical and Translational Oncology</i> , <b>2011</b> , 13, 121-32	3.6	5
75	Overview of preoperative radiochemotherapy in breast cancer: past or future?. <i>Clinical and Translational Oncology</i> , <b>2011</b> , 13, 446-50	3.6	4
74	A new era in the treatment of melanoma: from biology to clinical practice. <i>Clinical and Translational Oncology</i> , <b>2011</b> , 13, 787-92	3.6	9
73	Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 149-56	2.2	188
72	Bevacizumab treatment for advanced breast cancer. <i>Oncologist</i> , <b>2011</b> , 16, 1684-97	5.7	15
71	Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study. <i>Annals of Oncology</i> , <b>2011</b> , 22, 2591-2596	10.3	22
70	Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. <i>Oncologist</i> , <b>2011</b> , 16, 1092-100	5.7	181

69	A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 305, 1873-81	27.4	414
68	A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 2006-13	12.9	58
67	Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 859-67	2.2	158
66	Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3877-84	2.2	116
65	Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer. <i>British Journal of Cancer</i> , <b>2010</b> , 103, 1524-8	8.7	15
64	Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4594-600	2.2	467
63	BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 3988-97	12.9	32
62	Adjuvant docetaxel for high-risk, node-negative breast cancer. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 2200-10	59.2	149
61	Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 5351-61	12.9	153
60	Breast cancer: complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma. <i>Anti-Cancer Drugs</i> , <b>2010</b> , 21 Suppl 1, S19-22	2.4	3
59	Current controversies in the management of breast cancer. <i>Clinical and Translational Oncology</i> , <b>2010</b> , 12, 278-86	3.6	2
58	Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 123, 149-57	4.4	63
57	Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 122, 591-600	4.4	33
56	Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 121, 121-31	4.4	172
55	Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 122, 169-76	4.4	61
54	Missing data imputation using statistical and machine learning methods in a real breast cancer problem. <i>Artificial Intelligence in Medicine</i> , <b>2010</b> , 50, 105-15	7.4	240
53	Reply to L.C. Panasci. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, e112-e113	2.2	
52	Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1168-76	2.2	411

51	Reply to R.S. Mehta et al. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3068-3069	2.2	1
50	Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. <i>Oncologist</i> , <b>2009</b> , 14, 1-11	5.7	100
49	Reclassification of the members of the genus <i>Tetrathiobacter</i> Ghosh et al. 2005 to the genus <i>Advenella</i> Coenye et al. 2005. <i>International Journal of Systematic and Evolutionary Microbiology</i> , <b>2009</b> , 59, 1914-8	2.2	32
48	Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). <i>Clinical and Translational Oncology</i> , <b>2009</b> , 11, 363-75	3.6	11
47	Circulating tumour cells in locally advanced breast cancer. <i>Clinical and Translational Oncology</i> , <b>2009</b> , 11, 544-7	3.6	11
46	Prognostic and predictive factors and genetic analysis of early breast cancer. <i>Clinical and Translational Oncology</i> , <b>2009</b> , 11, 634-42	3.6	6
45	A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2009</b> , 64, 1139-48	3.5	45
44	Docetaxel-related side effects and their management. <i>European Journal of Oncology Nursing</i> , <b>2009</b> , 13, 49-59	2.8	160
43	A multicenter, single-arm phase II study of pemetrexed plus doxorubicin administered every 21 days in patients with advanced breast cancer. <i>Clinical Breast Cancer</i> , <b>2009</b> , 9, 155-60	3	2
42	TRIO-012: a multicenter, multinational, randomized, double-blind phase III study of IMC-1121B plus docetaxel versus placebo plus docetaxel in previously untreated patients with HER2-negative, unresectable, locally recurrent or metastatic breast cancer. <i>Clinical Breast Cancer</i> , <b>2009</b> , 9, 258-61	3	28
41	Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer. <i>Breast Cancer Research</i> , <b>2009</b> , 11, 204	8.3	24
40	Retrospective subset analyses in early breast cancer revisited. <i>Lancet Oncology, The</i> , <b>2009</b> , 10, 1136-7	21.7	
39	Unravelling the mystery of the TACT trial. <i>Lancet, The</i> , <b>2009</b> , 373, 1662-3	40	3
38	Time-to-progression in breast cancer: a stratification model for clinical trials. <i>Breast</i> , <b>2008</b> , 17, 239-44	3.6	1
37	Trans-generational radiation-induced chromosomal instability in the female enhances the action of chemical mutagens. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , <b>2008</b> , 640, 16-26	3.3	5
36	The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients. <i>European Journal of Cancer</i> , <b>2008</b> , 44, 353-65	7.5	16
35	Docetaxel-related side effects and their management. <i>European Journal of Oncology Nursing</i> , <b>2008</b> , 12, 253-68	2.8	31
34	Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2008</b> , 100, 805-14	9.7	174

33	Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 2636-43	2.2	44
32	Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007. <i>Clinical and Translational Oncology</i> , <b>2008</b> , 10, 552-9	3.6	1
31	Molecular haplotyping of tandem single nucleotide polymorphisms by allele-specific PCR. <i>Analytical Biochemistry</i> , <b>2007</b> , 364, 153-8	3.1	1
30	Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer. <i>Breast</i> , <b>2007</b> , 16 Suppl 2, S127-31	3.6	17
29	Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM). <i>Breast Cancer Research and Treatment</i> , <b>2007</b> , 101, 215-23	4.4	45
28	Elementary, my dear Watson. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1815-6	2.2	6
27	Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3399-406	2.2	250
26	A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 3652-9	12.9	24
25	Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. <i>Lancet Oncology</i> , <b>2007</b> , 8, 219-25	21.7	152
24	BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, LBA1008-LBA1008	2.2	21
23	Molecular biology of breast cancer. <i>Clinical and Translational Oncology</i> , <b>2006</b> , 8, 7-14	3.6	22
22	Circulating tumoral cells lack circadian-rhythm in hospitalized metastatic breast cancer patients. <i>Clinical and Translational Oncology</i> , <b>2006</b> , 8, 826-9	3.6	6
21	Clinical experience with pemetrexed in breast cancer. <i>Seminars in Oncology</i> , <b>2006</b> , 33, S15-8	5.5	8
20	Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. <i>Annals of Oncology</i> , <b>2006</b> , 17, 1205-12	10.3	153
19	Docetaxel, doxorubicin and cyclophosphamide (the TAC regimen): an effective adjuvant treatment for operable breast cancer. <i>Women's Health</i> , <b>2006</b> , 2, 527-37	3	12
18	Phase II study of ixabepilone in patients (pts) with taxane-resistant metastatic breast cancer (MBC): Final report. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 10505-10505	2.2	12
17	The global breast cancer burden: variations in epidemiology and survival. <i>Clinical Breast Cancer</i> , <b>2005</b> , 6, 391-401	3	346
16	Adjuvant docetaxel for node-positive breast cancer. <i>New England Journal of Medicine</i> , <b>2005</b> , 352, 2302-13	39.2	773

15	Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. <i>Clinical Breast Cancer</i> , <b>2005</b> , 6, 325-9	3	42
14	Capecitabine plus docetaxel combination therapy. <i>Cancer</i> , <b>2005</b> , 103, 2455-65	6.4	20
13	Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. <i>Annals of Oncology</i> , <b>2004</b> , 15, 79-87	10.3	55
12	Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 2587-93	2.2	109
11	Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure. <i>Clinical Breast Cancer</i> , <b>2004</b> , 5, 353-7	3	22
10	Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. <i>Annals of Oncology</i> , <b>2003</b> , 14, 1246-52	10.3	38
9	Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. <i>Annals of Oncology</i> , <b>2003</b> , 14, 833-42	10.3	130
8	Vinorelbine as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: a cooperative study by the GEICAM group. <i>Clinical Breast Cancer</i> , <b>2003</b> , 3, 399-404	3	13
7	Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 968-75	2.2	319
6	Moving forward with capecitabine: a glimpse of the future. <i>Oncologist</i> , <b>2002</b> , 7 Suppl 6, 29-35	5.7	4
5	Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy. <i>Breast Cancer Research</i> , <b>2001</b> , 3, 183-91	8.3	35
4	Methotrexate, uracil and tegafur, and leucovorin chemotherapy for patients with breast cancer in progression after high-dose chemotherapy with peripheral blood progenitor cell transplant: a phase II study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2000</b> , 23, 617-21	2.7	4
3	Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure. <i>Annals of Oncology</i> , <b>2000</b> , 11, 85-9	10.3	21
2	Effect of clavulanic acid and/or polymorphonuclear neutrophils on amoxicillin bactericidal activity against <i>Streptococcus pneumoniae</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , <b>1997</b> , 16, 512-6	5.3	11
1	Effect of oxodipine and nifedipine on guinea-pig ileum. <i>General Pharmacology</i> , <b>1988</b> , 19, 771-4		